Prompt injection in clinical trials and pharmaceutical AI

Four adversarial injection surfaces in clinical trials and pharmaceutical AI

1. Case Report Form paper scan AI injection (Medidata Rave AI, Oracle Clinical One AI, IBM Clinical Development AI)

Clinical trial Case Report Form (CRF) paper scan AI processes scanned images of paper CRFs completed by investigators at clinical trial sites — including handwritten patient data fields, investigator signatures, site stamps, source data verification initials, and date/time entries — through AI-assisted data extraction and transcription tools that convert paper source documents into electronic data records for submission to the sponsor’s clinical data management system (CDMS) and ultimately to the FDA electronic common technical document (eCTD) regulatory submission package. Medidata Rave’s AI data extraction and query management platform processes paper CRF scan images submitted by CRO monitors and data management teams through the Medidata Rave EDC interface for sponsors using hybrid paper/electronic data capture workflows — a workflow that remains prevalent in Phase III global trials where investigator sites in lower-infrastructure regions submit paper CRFs for centralised scanning and AI data extraction. Oracle Clinical One’s AI-assisted site data management processes source document scan images for patient enrollment verification, informed consent documentation review, and protocol eligibility confirmation for sponsors and CROs using the Oracle Clinical One eTMF (Trial Master File) and site activation platforms. IBM Clinical Development AI processes scanned CRF and source document images through AI data capture tools integrated into IBM’s clinical data management and statistical analysis platform used by pharmaceutical companies running complex adaptive trial designs.

The CRF paper scan submission pathway is the adversarial injection surface: scanned images of completed paper CRFs submitted through Medidata Rave EDC scan upload interfaces, Oracle Clinical One eTMF document management portals, or CRO data management scanning platforms for AI text extraction and transcription into the electronic clinical database. An adversarially crafted CRF paper scan — in which pixel perturbations applied to the printed or handwritten region of a patient vital sign reading, a protocol eligibility criterion check, an adverse event severity grade, or an investigator signature cause the Medidata Rave AI or Oracle Clinical One AI to extract incorrect data values or to classify the CRF field as completing a protocol eligibility requirement that was not actually satisfied — can introduce fabricated or altered data into the clinical trial database that forms the basis of the NDA or BLA (Biologics License Application) submission to FDA. The adversarial data manipulation motivation operates at two levels: a clinical investigator site under performance pressure to enroll eligible patients may adversarially craft CRF scan images to cause the AI to extract eligibility data that would otherwise result in a protocol deviation or screen failure, and a sponsor or CRO under trial timeline pressure may adversarially craft CRF scans to eliminate adverse event severity records that would otherwise trigger safety signal review obligations.

FDA regulatory consequences for clinical trial data integrity violations are among the most severe in pharmaceutical regulatory law. Under 21 CFR Part 11 (electronic records and signatures), the integrity of the data extraction pathway from paper source document to electronic clinical database is a GCP compliance obligation — an adversarially manipulated AI data extraction that introduces incorrect data into the electronic record without a detectable audit trail creates a 21 CFR Part 11 data integrity violation that FDA inspectors can identify during a pre-approval inspection (PAI). Under ICH E6(R2) GCP Guidelines (Section 5.1.3), the sponsor is required to implement data management procedures that ensure the accuracy and completeness of data collected at investigator sites — adversarial manipulation of CRF scan AI data extraction is a systematic failure of this obligation that FDA and EMA GCP inspectors have the authority to characterise as a GCP critical finding. The consequence of a GCP critical finding in a pre-approval inspection is a Complete Response Letter (CRL) from FDA, which can delay NDA approval by 12–24 months — a regulatory setback that represents hundreds of millions of dollars in lost market exclusivity revenue for a priority review product. Criminal prosecution risk under 18 USC § 1001 (false statements to federal agencies) applies to clinical trial data submissions that contain material false statements, including adversarially manipulated AI-extracted data that misrepresents patient safety or efficacy outcomes. Threshold: 50 for CRF paper scan AI (21 CFR Part 11 data integrity, ICH E6(R2) GCP, FDA PAI, NDA Complete Response Letter).

2. Clinical site monitoring photograph AI injection (Veeva Vault AI, Parexel IMPACT AI, ICON AI monitoring)

Clinical site monitoring AI processes photographs submitted by clinical research associates (CRAs) during site monitoring visits — including photographs of investigator delegation logs, informed consent form completion records, source data verification (SDV) evidence, temperature monitoring equipment, drug storage conditions, and patient enrollment logs — through AI-assisted monitoring workflow tools that classify site compliance status, identify protocol deviations and GCP deficiencies, and generate monitoring visit reports (MVRs) that are reviewed by sponsors and CROs for site risk categorisation and regulatory inspection readiness assessment. Veeva Vault Clinical Suite’s AI-assisted site monitoring workflow processes monitoring visit photographs for over 1,000 biopharmaceutical sponsors, generating AI-assisted monitoring visit report summaries, deviation identification, and CAPA (Corrective and Preventive Action) tracking from site visit evidence photographs submitted through the Veeva Vault RIM and CTMS platforms. Parexel’s IMPACT AI monitoring platform processes site visit evidence photographs for Parexel-managed trials, using AI to classify site compliance status and generate risk-adaptive monitoring (RAM) visit frequency recommendations based on site performance indicators including protocol deviation rates and SDV findings from monitoring photograph evidence. ICON plc’s AI-assisted site monitoring platform processes evidence photographs from ICON CRA site visits across ICON’s global clinical trial site network covering over 100 countries, generating AI-assisted MVR content and deviation tracking for sponsors using ICON’s functional service provider and full-service CRO models.

The site monitoring photograph submission pathway is the adversarial injection surface: photographs taken by CRAs during site monitoring visits using tablets or smartphones and submitted through Veeva Vault, Parexel IMPACT, or ICON monitoring workflow apps for AI compliance classification and deviation identification. An adversarially crafted site monitoring photograph — in which pixel perturbations applied to image regions showing a temperature monitoring log with an out-of-range excursion, an informed consent form with a missing patient signature, or a delegation log with an uncertified staff member performing protocol-delegated procedures cause the Veeva Vault AI or Parexel IMPACT AI to classify the compliance indicator as conforming to GCP requirements when the physical evidence photographed shows a protocol deviation — can result in a monitoring visit report that fails to identify a protocol deviation that the CRA’s physical site examination observed, suppressing the CAPA that would otherwise be required for the deviation. The adversarial suppression motivation in site monitoring AI is site performance driven: investigator sites with high deviation rates face enhanced monitoring frequency, risk categorisation changes, and in the most serious cases, site closure — creating a site-level financial and operational incentive to ensure monitoring visit photographs are classified as compliant.

The regulatory consequence of adversarially suppressed protocol deviations in site monitoring AI is a corrupted monitoring record that creates false assurance of site GCP compliance in the trial master file (TMF). Under ICH E6(R2) GCP Section 5.18 (monitoring), the sponsor is required to ensure that trial site compliance with the protocol, SOPs, GCP, and applicable regulatory requirements is verified through monitoring — an adversarially manipulated monitoring AI that fails to identify observable protocol deviations creates a systematic monitoring failure that FDA and EMA inspectors reviewing the TMF during a GCP inspection can characterise as a failure of sponsor oversight obligations. For pivotal efficacy trials supporting NDA or BLA approval, a systematic monitoring failure identified in a pre-approval inspection creates a CRL or clinical hold risk that is among the most commercially significant regulatory setbacks in pharmaceutical drug development — a pivotal trial whose data integrity is called into question by GCP inspection findings may require a complete re-monitoring exercise or additional confirmatory trial data before FDA will approve the NDA. The EMA GCP inspection process, which operates through the European Medicines Agency and national competent authority (NCA) GCP inspectors, applies the same ICH E6(R2) standards and can impose a GCP inspection finding that triggers a Mutual Recognition Agreement (MRA) notification to other regulatory agencies including FDA, Health Canada, and TGA. Threshold: 50 for clinical site monitoring photograph AI (ICH E6(R2) monitoring, FDA/EMA GCP inspection, NDA CRL risk, TMF integrity).

3. Pharmaceutical stability sample AI injection (Thermo Fisher SampleManager AI, Waters Empower AI, IDBS E-WorkBook AI)

Pharmaceutical stability testing AI processes photographs and images of stability sample chambers, stability sample vials and tablets, and visual inspection results generated during ICH Q1A(R2)-compliant stability studies to classify stability sample condition, detect degradation indicators (discolouration, precipitation, particulate formation, physical form change), and generate stability data records that form the long-term and accelerated stability data packages included in NDA, ANDA (Abbreviated New Drug Application), and MAA regulatory submissions. Thermo Fisher Scientific’s SampleManager AI LIMS processes stability sample images and visual inspection results for pharmaceutical quality control laboratories at major pharma manufacturers, generating AI-assisted stability data records that are linked to the stability protocol ICH Q1A(R2) specification and included in the stability section of FDA and EMA regulatory submissions. Waters Corporation’s Empower AI chromatography data system processes analytical instrument output images and stability sample visual inspection photographs for pharmaceutical quality control and stability testing laboratories, integrating AI-assisted data review tools that flag out-of-specification results in stability data series. IDBS E-WorkBook AI processes electronic laboratory notebook (ELN) stability data and stability sample photograph records for pharmaceutical R&D organisations, generating AI-assisted stability data summaries and trend analysis for NDA stability data package compilation.

The adversarial injection surface is the stability sample photograph and visual inspection image submission pathway: photographs of stability sample vials, tablets, and capsules captured at stability testing time points (T3, T6, T12, T24 months) and submitted through SampleManager, Empower, or IDBS E-WorkBook stability testing workflow interfaces for AI visual inspection classification. An adversarially crafted stability sample photograph — in which pixel perturbations applied to image regions showing tablet discolouration, solution precipitation, or particulate formation in a stability sample vial cause the SampleManager AI or Waters Empower AI to classify the stability observation as “no significant change” when the actual sample condition shows a stability-indicating degradation that exceeds the ICH Q1A(R2) acceptance criteria for the stability specification — can result in an NDA or ANDA stability data package that misrepresents the drug substance or drug product’s stability profile, potentially supporting a shelf-life (expiry date) claim that is not supported by actual stability performance. The adversarial stability data falsification motivation is product lifecycle driven: a pharmaceutical manufacturer facing a stability failure that would require shortening the approved shelf life of a marketed product — with the associated supply chain, inventory, and commercial impact — faces significant pressure on the stability testing AI workflow that determines the regulatory action threshold for stability specification non-conformance.

FDA regulatory consequences for stability data falsification are captured under 21 CFR Part 211.68 (automatic, mechanical, and electronic equipment) and 21 CFR Part 211.192 (production record review), which impose data integrity obligations on pharmaceutical manufacturers’ laboratory systems including AI-assisted stability testing tools. An NDA or ANDA stability data package that includes adversarially manipulated AI visual inspection records is a material misrepresentation in a federal regulatory submission, creating criminal exposure under 18 USC § 1001. The FDA’s Data Integrity and Compliance with Drug CGMP Guidance (March 2018) specifically addresses the obligation to ensure that computerised systems used to generate stability data records maintain data integrity — adversarial manipulation of AI stability image classification is a systematic computerised system integrity failure that falls squarely within the FDA’s CGMP data integrity enforcement framework. Post-approval stability failure — where an approved drug product’s stability profile degrades below specification during the approved shelf life because the NDA stability data was adversarially manipulated — creates a product recall obligation under 21 CFR Part 7 and potential criminal liability for the individuals responsible for the NDA submission. Threshold: 50 for pharmaceutical stability sample AI (21 CFR Part 211.68, FDA CGMP data integrity, ICH Q1A(R2), NDA stability package integrity).

4. Biobank specimen label AI injection (LabVantage LIMS AI, Labware LIMS AI, BioMatik AI biobank management)

Biobank specimen label AI processes scanned images and photographs of biobank specimen labels, cryogenic vial labels, and sample aliquot labels submitted through laboratory information management system (LIMS) interfaces and biobank management platforms to read specimen identifiers, patient ID codes, cohort assignment codes, collection date and time, storage condition specifications, and chain-of-custody records for clinical trial sample tracking and cohort assignment management. LabVantage LIMS AI processes specimen label scan images for pharmaceutical research biobanks at major pharmaceutical companies and academic medical centres, integrating AI label reading with automated sample workflow management and clinical trial CTMS integrations that link specimens to patient records in the clinical database. Labware LIMS AI processes biobank specimen label images for clinical and pharmaceutical laboratory environments, using AI-assisted label reading to maintain chain-of-custody records and storage condition compliance tracking for regulatory submissions requiring specimen integrity documentation. BioMatik’s AI biobank management platform and Freezerworks AI process cryogenic specimen label images for biobanks supporting clinical trials, biomarker research programs, and translational research studies where specimen cohort assignment accuracy is critical to the scientific validity of the study conclusions.

The adversarial injection surface is the biobank specimen label scan and photograph submission pathway: scanned images of paper and cryogenic specimen labels submitted through LabVantage, Labware, or Freezerworks LIMS label reading interfaces for AI specimen identifier extraction and cohort assignment processing. An adversarially crafted specimen label scan — in which pixel perturbations applied to the label’s patient ID barcode, cohort assignment code, collection date, or treatment arm identifier region cause the LabVantage LIMS AI or Labware AI to read an incorrect patient ID, assign the specimen to the wrong clinical trial cohort, or associate the specimen with the wrong collection date — can result in a biobank specimen being linked to the wrong patient record in the clinical database, assigned to the wrong treatment arm cohort for biomarker analysis, or excluded from or included in a time-point data set based on an incorrect collection date association. The adversarial specimen label manipulation motivation in biobank AI ranges from competitive research data manipulation — reassigning specimens between treatment arm cohorts to distort biomarker outcome data in a clinical trial that will inform a regulatory submission — to operational pressure-driven manipulation where a biobank manager responsible for a specimen with a processing error labels it adversarially to avoid recording a protocol deviation in the biobank specimen chain-of-custody record.

Informed consent and patient data integrity consequences of biobank specimen label AI manipulation follow from 45 CFR Part 46 (Common Rule, Protection of Human Subjects) and 21 CFR Part 50 (Protection of Human Subjects in clinical investigations regulated by FDA), which require that human subject specimens be linked to informed consent records and used only for the purposes consented by the patient. Adversarial specimen label AI manipulation that causes a specimen to be assigned to a patient record for which the patient did not consent to that specific biomarker research use creates an informed consent protocol violation — a GCP deviation with IRB (Institutional Review Board) and FDA reporting obligations under 21 CFR Part 312.62 (investigator records and reports). Scientific validity consequences are the most direct: a clinical trial biomarker analysis that is based on specimens adversarially misassigned to incorrect treatment arm cohorts generates scientifically invalid biomarker outcome data that supports a regulatory conclusion — for example, a companion diagnostic biomarker that appears to predict treatment response because the AI assigned specimens from the responding patient cohort to the biomarker-positive label when the physical specimens were from the non-responding cohort. The FDA’s Guidance for Industry on Bioanalytical Method Validation (May 2018) and ICH M10 Bioanalytical Method Validation Guideline impose sample management integrity requirements for bioanalytical studies supporting regulatory submissions. Threshold: 50 for biobank specimen label AI (21 CFR Part 50 informed consent, ICH E6(R2) specimen management, FDA bioanalytical validation, scientific validity).

Integration: clinical trial and pharmaceutical AI image ingestion with Glyphward pre-scan

Clinical trial and pharmaceutical AI image ingestion flows from CRF paper scan upload portals, site monitoring visit photograph APIs, stability sample imaging system interfaces, and biobank specimen label scanning platforms into AI GCP data extraction, compliance monitoring, stability assessment, and specimen management pipelines. Insert Glyphward’s pre-scan at the ingestion boundary — in all clinical trial and pharmaceutical contexts, because the regulatory and scientific integrity consequences of adversarial image manipulation in these workflows are categorically higher than in commercial AI applications:

import asyncio
import base64
import hashlib
import os
import uuid
from enum import Enum
from pathlib import Path

import httpx

GLYPHWARD_API_KEY = os.environ["GLYPHWARD_API_KEY"]
GLYPHWARD_SCAN_URL = "https://glyphward.com/v1/scan"

# Clinical trial AI — GCP data integrity (21 CFR Part 11, ICH E6(R2)),
# FDA inspection (Form 483, Warning Letter, CRL), NDA/ANDA stability package
# integrity, informed consent specimen management (45 CFR Part 46).
# Threshold 50 across all clinical contexts — the regulatory and patient safety
# consequences of a false negative (allowing adversarial image through) exceed
# the operational cost of a false positive (human review of flagged image).
THRESHOLD_CLINICAL = 50


class ClinicalAIContext(str, Enum):
    CRF_SCAN           = "crf_scan"           # Medidata Rave, Oracle Clinical One
    SITE_MONITORING    = "site_monitoring"     # Veeva Vault, Parexel IMPACT, ICON
    STABILITY_SAMPLE   = "stability_sample"   # SampleManager, Empower, IDBS EWB
    SPECIMEN_LABEL     = "specimen_label"     # LabVantage, Labware, Freezerworks


async def scan_clinical_image(
    image_path: str | Path,
    context: ClinicalAIContext,
    protocol_hash: str,         # SHA-256 of protocol number — trial linkage without PII
    site_hash: str,             # SHA-256 of site ID — site linkage without PII
    document_ref: str,          # e.g. "crf_v2_page3", "mvr_2026Q1_temp_log"
    client: httpx.AsyncClient,
) -> dict:
    """
    Scan a clinical trial or pharmaceutical AI image for adversarial injection
    payloads before forwarding to CRF data extraction AI, site monitoring
    compliance AI, stability sample assessment AI, or biobank specimen label AI.

    Raises AdversarialClinicalImageError if the Glyphward score meets or
    exceeds the clinical threshold (50). The 50-threshold policy reflects
    that the regulatory cost of a GCP data integrity false negative exceeds
    the operational cost of routing a borderline image for human review.
    """
    image_bytes = Path(image_path).read_bytes()
    image_b64 = base64.b64encode(image_bytes).decode()
    image_sha256 = hashlib.sha256(image_bytes).hexdigest()
    scan_id = str(uuid.uuid4())

    resp = await client.post(
        GLYPHWARD_SCAN_URL,
        headers={"Authorization": f"Bearer {GLYPHWARD_API_KEY}"},
        json={
            "image": image_b64,
            "source": context.value,
            "metadata": {
                "clinical_context": context.value,
                "protocol_hash": protocol_hash,
                "site_hash": site_hash,
                "document_ref": document_ref,
                "client_scan_id": scan_id,
                "image_sha256": image_sha256,
            },
        },
        timeout=10.0,
    )
    resp.raise_for_status()
    result = resp.json()

    audit_record = {
        "protocol_hash": protocol_hash,
        "site_hash": site_hash,
        "document_ref": document_ref,
        "clinical_context": context.value,
        "scan_id": result["scan_id"],
        "client_scan_id": scan_id,
        "image_sha256": image_sha256,
        "score": result["score"],
        "flagged_region": result.get("flagged_region"),
        "threshold": THRESHOLD_CLINICAL,
        "action": "blocked" if result["score"] >= THRESHOLD_CLINICAL else "allowed",
    }
    await write_gcp_audit_record(audit_record)

    if result["score"] >= THRESHOLD_CLINICAL:
        raise AdversarialClinicalImageError(
            f"Clinical AI image blocked [{context.value}]: "
            f"scan_id={result['scan_id']} score={result['score']} "
            f"protocol_hash={protocol_hash} doc_ref={document_ref}"
        )
    return result


async def scan_crf_batch(
    page_paths: list[Path],
    protocol_hash: str,
    site_hash: str,
    crf_ref: str,
) -> dict:
    """
    Scan all pages of a paper CRF scan set before loading into Medidata Rave /
    Oracle Clinical One AI data extraction. Threshold 50 (GCP data integrity).
    """
    allowed, blocked, errors = [], [], []
    async with httpx.AsyncClient() as client:
        tasks = [
            scan_clinical_image(
                p, ClinicalAIContext.CRF_SCAN,
                protocol_hash, site_hash, f"{crf_ref}_page{i+1}", client,
            )
            for i, p in enumerate(page_paths)
        ]
        results = await asyncio.gather(*tasks, return_exceptions=True)

    for path, result in zip(page_paths, results):
        if isinstance(result, AdversarialClinicalImageError):
            blocked.append({"path": str(path), "error": str(result)})
        elif isinstance(result, Exception):
            errors.append({"path": str(path), "error": str(result)})
        else:
            allowed.append({"path": str(path), "scan_id": result["scan_id"]})

    return {
        "protocol_hash": protocol_hash,
        "site_hash": site_hash,
        "crf_ref": crf_ref,
        "total": len(page_paths),
        "allowed": len(allowed),
        "blocked": len(blocked),
        "errors": len(errors),
        "blocked_pages": blocked,
    }


async def write_gcp_audit_record(record: dict) -> None:
    """Persist GCP audit record to validated audit trail store (stub)."""
    import json, sys
    print(json.dumps(record), file=sys.stderr)


class AdversarialClinicalImageError(Exception):
    """Raised when a clinical AI image exceeds the adversarial injection threshold."""
    pass

Call scan_crf_batch() before forwarding paper CRF page scan image sets to Medidata Rave AI or Oracle Clinical One AI data extraction — CRF batch scanning at threshold 50 is the highest-priority integration point in the clinical trial AI pipeline because the CRF data chain is the primary source of efficacy and safety data in the NDA submission. Call scan_clinical_image() with ClinicalAIContext.SITE_MONITORING for all monitoring visit evidence photographs before Veeva Vault AI, Parexel IMPACT AI, or ICON AI monitoring workflow classification. Call with ClinicalAIContext.STABILITY_SAMPLE for stability sample condition photographs before SampleManager AI, Waters Empower AI, or IDBS E-WorkBook AI stability assessment at each ICH Q1A(R2) stability testing time point. Call with ClinicalAIContext.SPECIMEN_LABEL for all biobank specimen label scan images before LabVantage or Labware LIMS AI label reading and specimen assignment. The protocol_hash and site_hash parameters link audit records to specific trials and sites using SHA-256 hashes, enabling GCP audit trail reconstruction for FDA and EMA inspectors without transmitting patient-linked or site-identifying data to the Glyphward API boundary. The Glyphward audit record — including image_sha256, score, threshold, and action — should be stored in the trial master file (TMF) as evidence of the data integrity verification measure for FDA and EMA GCP inspection readiness. Get early access

Coverage matrix

Frequently asked questions

Further reading

• Indirect prompt injection via image — foundational attack pattern underlying all four clinical trial AI injection surfaces; covers how adversarial pixel-level perturbations cause AI misclassification through image content manipulation without detectable visual artifacts.
• Prompt injection scanner for healthcare AI — healthcare AI security covering clinical decision support, medical imaging AI, and EHR AI with overlapping FDA regulatory and HIPAA compliance considerations.
• HIPAA-compliant AI security and prompt injection — HIPAA data integrity and security considerations for AI systems processing protected health information in clinical trial contexts.
• PDF prompt injection detection — document-based injection vectors relevant to eCTD submission PDFs, clinical study report PDFs, and regulatory correspondence in NDA/ANDA workflows.
• Free tier — 10 scans/day, no card required — start scanning clinical trial AI images at development volumes before committing to a production plan.